Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
NCT04404140 · Hoffmann-La Roche · PHASE1 · terminated · last registry update 2023-10-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab and docetaxel was challenging due to multiple study treatment modifications required to manage toxicity, making further enrollment inappropriate.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-10Phase 3 first posted: AstraZeneca, Capivasertib + Fulvestrant (NCT06635447)
- 2024-06-20Results posted on the registry: AstraZeneca, Capivasertib (NCT05008055)
- 2024-06-14Results posted on the registry: Hoffmann-La Roche, Alectinib + Vismodegib (NCT03498521)
- 2024-06-04Also stopped (terminated): Merck Sharp & Dohme LLC, MK-2206 + Trastuzumab (NCT00963547)
- 2024-03-27Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Ipatasertib (NCT04177108)
- 2024-03-12Results posted on the registry: Hoffmann-La Roche, Ipatasertib + Paclitaxel (NCT03337724)
- 2023-11-13Results posted on the registry: David VanderWeele, Ipatasertib + Darolutamide (NCT04737109)
- 2023-11-13Also stopped (terminated): David VanderWeele, Ipatasertib + Darolutamide (NCT04737109)
- 2023-10-30Results posted on the registry: Hoffmann-La Roche, Ipatasertib + Rucaparib (NCT03840200)
- 2023-09-14Results posted on the registry: Genentech, Inc., Abiraterone + Apitolisib (NCT01485861)
- 2023-05-17Phase 3 first posted: Hoffmann-La Roche, Ipatasertib + Tiragolumab (NCT05862285)
- 2023-04-13Also stopped (terminated): ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Miransertib (NCT03094832)
- 2023-04-11Results posted on the registry: National Cancer Institute (NCI), AZD6244 + MK-2206 (NCT01306045)
- 2023-04-10Results posted on the registry: Hoffmann-La Roche, Ipatasertib + Abiraterone (NCT03072238)
- 2023-03-31Results posted on the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Miransertib (NCT03094832)
- 2023-03-21Results posted on the registry: City of Hope Medical Center, Atezolizumab + Capecitabine (NCT03853707)
- 2022-12-28Results posted on the registry: Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
- 2022-12-28Also stopped (terminated): Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision